TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25395429

Group type: EXPERIMENTAL
Intervention: Dinaciclib at 30 mg/m²
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dinaciclib at 40 mg/m²
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dinaciclib at 50 mg/m²
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dinaciclib (overall)
Number of subjects: 27
Study: 25396060

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25(OH)D levels <20 ng/mL)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 201
Study: 25396065

Group type: EXPERIMENTAL
Intervention: Belimumab (SRI responders, n=761)
Number of subjects: 1684
Study: 25396067

Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 201
Study: 25397516

Group type: EXPERIMENTAL
Intervention: DRV/COBI 800/150 mg qd plus two fully active N[t]RTIs
Number of subjects: 295
Study: 25397527

Group type: EXPERIMENTAL
Intervention: etravirine (ETR) 200 mg bid with an optimised background regimen (BR) excluding DRV/r or NRTIs only
Number of subjects: 211
Study: 25398082

Group type: EXPERIMENTAL
Intervention: Training of unlicensed healthcare providers in zinc treatment and diarrhoea management
Number of subjects: 2
Study: 25398099

Group type: EXPERIMENTAL
Intervention: Monitoring for delirium in clinical routine
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Use of a validated delirium score
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Actual practice of delirium monitoring
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Sedation levels
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Pain assessment tools implementation
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Pain in patients
Number of subjects: 868
Study: 25398578

Group type: EXPERIMENTAL
Intervention: Hospitalization in cognitive and behavioral units
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at months 3, 6, and 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term follow-up for 12 months post-hospitalization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of rehospitalization for behavioral disorders
Number of subjects: 0
Study: 25398652

Group type: EXPERIMENTAL
Intervention: 2013 state health department survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top ways to encourage EBDM use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Most important items for applying EBDM
Number of subjects: 0
Study: 25398832

Group type: EXPERIMENTAL
Intervention: Bendamustine, bortezomib and dexamethasone
Number of subjects: 0
Study: 25399249

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy with adaptive difficulty levels
Number of subjects: 6
Study: 25399542

Group type: EXPERIMENTAL
Intervention: Large serrated polyps (≥10 mm in diameter)
Number of subjects: 12955

Group type: EXPERIMENTAL
Intervention: Advanced adenomas
Number of subjects: 12955

Group type: EXPERIMENTAL
Intervention: Non-advanced adenomas
Number of subjects: 12955

Group type: EXPERIMENTAL
Intervention: Large serrated polyps
Number of subjects: 12955

Group type: EXPERIMENTAL
Intervention: Large serrated polyps left in situ
Number of subjects: 12955
Study: 25399779

Group type: EXPERIMENTAL
Intervention: Levosimendan (administered immediately after anaesthesia induction)
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Levosimendan (administered later after postoperative ICU admission)
Number of subjects: 1095
Study: 25400468

Group type: EXPERIMENTAL
Intervention: Neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy followed by laparoscopic mesorectal excision.
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Withholding adjuvant chemotherapy after complete response following standard neoadjuvant chemoradiotherapy and laparoscopic mesorectal excision.
Number of subjects: 176
Study: 25400592

Group type: EXPERIMENTAL
Intervention: High aerobic intensity training (HIT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No training
Number of subjects: 53
Study: 25401382

Group type: EXPERIMENTAL
Intervention: Rituximab for remission induction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab for remission maintenance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapies
Number of subjects: 0
Study: 25401784

Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Number of subjects: 286
Study: 25402214

Group type: EXPERIMENTAL
Intervention: STEMO (specialized ambulance)
Number of subjects: 6182

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 6182

Group type: EXPERIMENTAL
Intervention: Golden hour thrombolysis
Number of subjects: 6182
Study: 25402221

Group type: EXPERIMENTAL
Intervention: Deferasirox 30 mg/kg/d
Number of subjects: 16
Study: 25402488

Group type: EXPERIMENTAL
Intervention: (131)I-CLR1404, 370 MBq single injection
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: (131)I-CLR1404, 740 MBq predicted administration
Number of subjects: 8
Study: 25403092

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) with pre-dilation (BAV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI) without pre-dilation (BAV)
Number of subjects: 0
Study: 25403209

Group type: EXPERIMENTAL
Intervention: 3.0 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.3 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: recombinant human IL-15 (rhIL-15) administration
Number of subjects: 0
Study: 25403217

Group type: EXPERIMENTAL
Intervention: Atu027 (10 escalating doses, 0.336 mg/kg, intravenous infusions twice per week during a 28-day cycle)
Number of subjects: 34
Study: 25403550

Group type: EXPERIMENTAL
Intervention: High physical activity level
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Moderate physical activity level
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Low physical activity level
Number of subjects: 988
Study: 25403830

Group type: EXPERIMENTAL
Intervention: vosaroxin 72 mg/m² d 1, 4
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: vosaroxin 72 mg/m² d 1, 8, 15
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: vosaroxin 72 mg/m² d 1, 8
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: vosaroxin 90 mg/m² d 1, 4
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: vosaroxin (all schedules)
Number of subjects: 116
Study: 25404094

Group type: EXPERIMENTAL
Intervention: Belinostat (1000 mg/m² intravenously ×5 days of a 21-day cycle)
Number of subjects: 53
Study: 25404145

Group type: EXPERIMENTAL
Intervention: Transference Work Scale (TWS)
Number of subjects: 0
Study: 25404412

Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: QuantiFERON(®)-TB GOLD (QFT-G)
Number of subjects: 308
Study: 25404952

Group type: EXPERIMENTAL
Intervention: 30 mg of LY2811376
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 90 mg of LY2811376
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 25405275

Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 84
Study: 25405351

Group type: EXPERIMENTAL
Intervention: Baminercept (lymphotoxin-beta receptor-immunoglobulin fusion protein)
Number of subjects: 0
Study: 25405497

Group type: EXPERIMENTAL
Intervention: Leptin concentrations
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Adiponectin concentrations
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Ghrelin concentrations
Number of subjects: 634
Study: 25405500

Group type: EXPERIMENTAL
Intervention: Dyskeratosis congenita (DC)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diamond-Blackfan anemia (DBA)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fanconi anemia (FA)
Number of subjects: 5
Study: 25405614

Group type: EXPERIMENTAL
Intervention: 14-day antibiotic therapy during acute exacerbations
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Bronchiectasis symptoms for 10 years or greater
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Sputum culture positive for Pseudomonas aeruginosa
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: HRCT total score being 12 or greater
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 4 or more bronchiectatic lobes
Number of subjects: 142
Study: 25405619

Group type: EXPERIMENTAL
Intervention: High for age carotid-femoral pulse wave velocity (PWV)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Known hypertension
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Presence of carotid plaque
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Higher systolic BP
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Low HDL cholesterol
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Higher serum creatinine
Number of subjects: 205
Study: 25405724

Group type: EXPERIMENTAL
Intervention: NF54 strain Plasmodium falciparum by the bite of five infected Anopheles stephensi mosquitoes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Chloroquine by directly observed therapy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Monitoring for signs and symptoms of malaria and for parasitemia by peripheral blood smear
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: qRT-PCR
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Antibody response to merozoite surface protein 1 (MSP-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Humoral and cellular responses to pre-erythrocytic antigens CSP and LSA-1
Number of subjects: 6
Study: 25406275

Group type: EXPERIMENTAL
Intervention: Latent class analysis (LCA) of fundus autofluorescence (FAF) patterns
Number of subjects: 171

Group type: COMPARATOR
Intervention: Original classification of FAF patterns
Number of subjects: 171
Study: 25406369

Group type: EXPERIMENTAL
Intervention: BAsE-Seq method for obtaining long haplotypes from short sequence reads
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BAsE-Seq applied to a clinical sample
Number of subjects: 0
Study: 25406639

Group type: EXPERIMENTAL
Intervention: Locking compression plate (LCP) for the superior anterior clavicle (Synthes®)
Number of subjects: 20
Study: 25406723

Group type: EXPERIMENTAL
Intervention: Autologous transplantation of mesenchymal stem cells
Number of subjects: 14
Study: 25406739

Group type: EXPERIMENTAL
Intervention: Endothelium-dependent, flow-mediated vasodilation (FMD) technique using high-resolution B-mode ultrasound
Number of subjects: 0
Study: 25407698

Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention program including diet and physical exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study: 25408112

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration at admission in ADHF patients
Number of subjects: 132

Group type: COMPARATOR
Intervention: Angiopoietin-2 concentration at admission in healthy controls
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration in ADHF patients with peripheral oedema
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration in ADHF patients without peripheral oedema
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration in ADHF patients with NYHA class III or IV symptoms
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration in ADHF patients with NYHA class II symptoms
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration at discharge in survivors
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration at admission in non-survivors
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration at discharge in non-survivors
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentrations at discharge above 2,500 pg/ml
Number of subjects: 132
Study: 25408147

Group type: EXPERIMENTAL
Intervention: SFRP4 concentrations
Number of subjects: 504
Study: 25408662

Group type: EXPERIMENTAL
Intervention: lanreotide Autogel(®) 120 mg, administered as monthly deep-subcutaneous injections
Number of subjects: 1

Group type: COMPARATOR
Intervention: octreotide long-acting release (LAR) 30 mg monthly
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: chemotherapy treatment with cisplatinum-etoposide
Number of subjects: 1
Study: 25409372

Group type: EXPERIMENTAL
Intervention: AAV8 vector gene therapy (high dose: 2×10(12) vector genomes per kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AAV8 vector gene therapy (high dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AAV8 vector gene therapy
Number of subjects: 10
Study: 25410548

Group type: EXPERIMENTAL
Intervention: Standardized operating room to intensive care unit handoff process
Number of subjects: 0
Study: 25411038

Group type: EXPERIMENTAL
Intervention: Children with elevated HRP2
Number of subjects: 451

Group type: COMPARATOR
Intervention: Adjustment for HRP2 and APP
Number of subjects: 451
Study: 25411281

Group type: EXPERIMENTAL
Intervention: Discovery GWA analysis
Number of subjects: 2403

Group type: EXPERIMENTAL
Intervention: Second-stage analysis
Number of subjects: 2403
Study: 25411597

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 12.5 mg
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 25 mg
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 100 mg
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Ipragliflozin (all doses)
Number of subjects: 361
Study: 25411598

Group type: EXPERIMENTAL
Intervention: soluble β-1,3/1,6-glucan (SBG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: methylcellulose (control)
Number of subjects: 60
Study: 25411804

Group type: EXPERIMENTAL
Intervention: Automated scoring using ApneaLink Plus monitor
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Automated scoring using Embletta monitor
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual scoring
Number of subjects: 200
Study: 25411976

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 82
Study: 25412225

Group type: EXPERIMENTAL
Intervention: Viral infection during exacerbations
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Virus-positive exacerbations
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Serum interferon-γ-induced protein 10
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: IV antibiotics
Number of subjects: 119
Study: 25413133

Group type: EXPERIMENTAL
Intervention: Inhalation of NO and oxygen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Maximal bicycle exercise
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 16

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 16
Study: 25413378

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.42
Number of subjects: 260

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: TEG variables (general)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: TEG variables (specific)
Number of subjects: 260
Study: 25414187

Group type: EXPERIMENTAL
Intervention: Camera-connected prosthesis (Argus II)
Number of subjects: 3
Study: 25415228

Group type: EXPERIMENTAL
Intervention: MCT1/2 inhibitor (AR-C155858)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oligomycin A (inhibitor of mitochondrial ATP synthase)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study: 25416075

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Instant soy porridge
Number of subjects: 87
Study: 25416418

Group type: EXPERIMENTAL
Intervention: Self-management strategies for CKD
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Health care providers' awareness of treatment burden
Number of subjects: 34
Study: 25416753

Group type: EXPERIMENTAL
Intervention: Intranasal administration of wild-type A(H1N1)pdm09 virus at an optimal dose of 10(7) tissue culture infectious dose 50.
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intranasal administration of wild-type A(H1N1)pdm09 virus.
Number of subjects: 69
Study: 25416807

Group type: EXPERIMENTAL
Intervention: Daclizumab therapy
Number of subjects: 0
Study: 25416917

Group type: EXPERIMENTAL
Intervention: 12-week nutritional intervention promoting the Mediterranean diet (MedDiet) based on Self-Determination Theory (SDT)
Number of subjects: 123
Study: 25417733

Group type: EXPERIMENTAL
Intervention: 50 Gy total dose with target volumes defined on pre-RT FDG-PET/CT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 Gy with boost target volume defined on FDG-PET/CT during RT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 66 Gy with target volumes from pre-RT FDG-PET/CT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 66 Gy with boost target volume from during-RT FDG-PET/CT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: During-RT FDG-PET/CT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 66 Gy planning on during-RT PET
Number of subjects: 10
Study: 25417902

Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg/afuresertib 50 mg once daily continuously
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg/afuresertib 25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trametinib 1.0 mg/afuresertib 50 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg (continuous)/afuresertib 50 mg (Days 1-10 every 28 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of trametinib and afuresertib
Number of subjects: 20
Study: 25417909

Group type: EXPERIMENTAL
Intervention: Antiviral treatment (AT)
Number of subjects: 116
Study: 25417940

Group type: EXPERIMENTAL
Intervention: Regulating access to secondary and tertiary care and restricting free provider choice to the primary care level.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unregulated access to health-care services.
Number of subjects: 0
Study: 25418910

Group type: EXPERIMENTAL
Intervention: LVR-coil treatment
Number of subjects: 38
Study: 25419693

Group type: EXPERIMENTAL
Intervention: B-cell reconstitution following haploidentical BM transplantation and post-transplant CY
Number of subjects: 0
Study: 25419882

Group type: EXPERIMENTAL
Intervention: Patients with chronic adrenal insufficiency receiving follow-up questionnaires and phone contact for reported adrenal crisis.
Number of subjects: 423
Study: 25420620

Group type: EXPERIMENTAL
Intervention: Flow cytometric sorting of human sperm (MicroSort®)
Number of subjects: 4993

Group type: EXPERIMENTAL
Intervention: IUI (Intrauterine Insemination)
Number of subjects: 4993

Group type: EXPERIMENTAL
Intervention: IVF/ICSI (In Vitro Fertilization/Intracytoplasmic Sperm Injection)
Number of subjects: 4993

Group type: EXPERIMENTAL
Intervention: FET (Frozen Embryo Transfer)
Number of subjects: 4993
Study: 25421091

Group type: EXPERIMENTAL
Intervention: 3 mg/infusion of recombinant human sulphamidase (rhSGSH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 mg/infusion of recombinant human sulphamidase (rhSGSH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 mg/infusion of recombinant human sulphamidase (rhSGSH) at fortnightly intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 mg/infusion of recombinant human sulphamidase (rhSGSH) at monthly intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3 mg/infusion of recombinant human sulphamidase (rhSGSH) at fortnightly intervals
Number of subjects: 0
Study: 25421474

Group type: EXPERIMENTAL
Intervention: Chloroquine treatment regimen
Number of subjects: 1806
Study: 25422275

Group type: EXPERIMENTAL
Intervention: Delirium (558 patients)
Number of subjects: 1112

Group type: COMPARATOR
Intervention: No delirium (554 patients)
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Delirium lasting 2 days or more (post hoc analysis)
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Delirium of any duration (competing risk analysis)
Number of subjects: 1112
Study: 25422771

Group type: EXPERIMENTAL
Intervention: Glimepiride/metformin fixed-dose combination (G/M FDC)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Metformin uptitration (Met UP)
Number of subjects: 209
Study: 25423261

Group type: EXPERIMENTAL
Intervention: Women with PCOS (overweight/obese)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Women with PCOS (lean)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Women without PCOS (overweight/obese)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Women without PCOS (lean)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Adiponectin to leptin ratios
Number of subjects: 422
Study: 25423570

Group type: EXPERIMENTAL
Intervention: Testicular sperm extraction (TESE) in Young group (15-22 years)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Testicular sperm extraction (TESE) in Adult group (> 23 years)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: TESE for patients with previous testosterone treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: TESE for patients without previous testosterone treatment
Number of subjects: 41
Study: 25424529

Group type: EXPERIMENTAL
Intervention: High Wells score (>4)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low Wells score (≤4)
Number of subjects: 79
Study: 25424783

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Hepatitis A control vaccine
Number of subjects: 1040
Study: 25424792

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0
Study: 25424932

Group type: EXPERIMENTAL
Intervention: Rotarix™ (2 doses)
Number of subjects: 2348